Association between acneiform eruption grade and survival outcomes in metastatic colorectal cancer patients treated with epidermal growth factor receptor inhibitors

Supplementary figures for Ong et al. Association between acneiform eruption grade and survival outcomes in metastatic colorectal cancer patients treated with epidermal growth factor receptor inhibitors. Supplementary figure 1: Progression-free survival in mCRC patients on EGFRis. Supplementary figure 1 legend: EGFRis, epidermal growth factor receptor inhibitors; g0, grade 0 rash; g1, grade 1 rash; g2/g3, grade 2/grade 3 rash; mCRC, metastatic colorectal cancer Median progression-free survival for grades 0, 1, and 2/3 rashes were 3.0, 5.5, and 5.1 months, respectively (p<0.001). Supplementary figure 2. Overall survival in mCRC patients on EGFRis. Supplementary figure 2 legend: EGFRis, epidermal growth factor receptor inhibitors; g0, grade 0 rash; g1, grade 1 rash; g2/g3, grade 2/grade 3 rash; mCRC, metastatic colorectal cancer Median overall survival for grades 0, 1, and 2/3 rashes were 6.8, 18.0, and 18.1 months, respectively (p<0.001).